Three Months After the Passing of Little Dog Rosie, Her Medical Records Transformed into an AI Healthcare Company

marsbitPublicado a 2026-08-24Actualizado a 2026-08-24

Resumen

Three months after the passing of his dog Rosie, AI entrepreneur Paul S. Conyngham secured $4 million in seed funding from Founders Fund for his new startup, Gamgee. The company aims to industrialize the experimental, AI-assisted process he pioneered to create a personalized mRNA cancer vaccine for Rosie, who suffered from mast cell tumors. With no formal biology background, Conyngham used AI tools like ChatGPT and AlphaFold to analyze Rosie's tumor DNA, identify target neoantigens, and design a custom mRNA vaccine sequence. Laboratory partners at UNSW produced the vaccine. Initial treatment showed tumor reduction, but Rosie's cancer later recurred and she was euthanized. Gamgee's goal is to streamline this "N-of-1" approach into a repeatable service for canine cancer patients, handling sequencing, vaccine design, production, and delivery. Clinical trials are planned in Australia in collaboration with research institutions. The company also eyes a longer-term vision of establishing personalized, mRNA-based medicine across species. The story highlights the broader challenge in personalized cancer treatment: compressing the entire timeline from design and regulatory approval to manufacturing and administration to match the patient's prognosis. While AI can accelerate target discovery, the remaining logistical and regulatory hurdles are significant. The article concludes by emphasizing that, for now, consulting qualified veterinary oncologists remains the responsible path for...

Yesterday, news of a 'successful cancer vaccine' directly caused a stir on Wall Street.

Moderna's stock price soared by 177% in a single day, marking one of the most dramatic single-day gains in recent years.

Why is capital so excited?

Because this new cancer treatment method sounds extremely 'sci-fi': first, read the genetic mutations in the patient's tumor, then create a customized mRNA vaccine for the patient.

Just as the entire industry was still immersed in this celebration, another 'miniaturized' mRNA cancer vaccine story reached a new milestone.

A few months ago, an AI entrepreneur without a medical background, Paul S. Conyngham, attempted to use AI tools like ChatGPT, Gemini, and Grok to "handcraft" a personalized mRNA vaccine for his cancer-stricken dog Rosie. This story quickly went viral online.

Just today, Paul announced that his newly founded company, Gamgee, secured $4 million in seed funding, led by Founders Fund.

This company aims to transform the plan initially tried for Rosie into a replicable process to provide personalized mRNA cancer vaccines for more dogs with cancer.

Regrettably, Rosie did not live to see the next chapter of this story.

The first sentence Paul wrote when announcing the funding was: "I lost my dog because we couldn't make her next mRNA cancer vaccine fast enough."

Rosie's Story

In March of this year, Rosie's story exploded on English-language social media: a tech entrepreneur with no biology training used AI tools to design a personalized mRNA cancer vaccine for his terminally ill dog, and several tumors shrank.

OpenAI CEO Sam Altman shared this story with his millions of followers.

Rosie was a Staffordshire Bull Terrier mix diagnosed with mast cell tumor — the most common skin cancer in dogs. Surgery and chemotherapy delayed the disease but didn't stop it, immunotherapy failed, and the veterinarian's prognosis was measured in "months".

Conyngham, on the other hand, has 17 years of experience in machine learning. According to Medical Daily, he spent around $3,000 out-of-pocket to conduct paired sequencing of Rosie's tumor DNA and healthy DNA at the University of New South Wales (UNSW). He then used AI to screen for neoantigens from thousands of mutations and used protein structure prediction to judge which ones might be "seen" by the immune system. According to a report by Reason, he used ChatGPT and AlphaFold to identify the mutant proteins, and ultimately used Grok for the construct design.

He did not make the vaccine himself. Researchers at the UNSW RNA Institute reviewed the data and manufactured the mRNA construct in the lab, with the institute's director, Pall Thordarson, leading the effort. To obtain ethical approval in Australia, Conyngham spent three months writing a 100-page document.

3D rendering of Rosie's healthy c-KIT protein using AlphaFold 2

Rosie received her first shot at a veterinary facility in Queensland in December 2025, followed by a booster the next month. Several of her tumors significantly shrank, and her quality of life improved. According to Y Combinator's company page, this is believed to be the first computationally designed mRNA cancer vaccine actually used on a dog.

Conyngham has always refused to call it a "cure."

The ending, as written in Gamgee's announcement: Rosie had gone into remission, but after a subsequent surgery, the cancer relapsed.

A more complete version comes from Conyngham's self-described account on X in June: That surgery took the cancer out of remission. Four weeks later, tumors rapidly spread across her hindquarters; she was in pain and was no longer the dog he knew. He made the decision for euthanasia, calling it the hardest decision of his life. He wrote that, in the truest sense, Rose was a pioneer.

Gamgee Aims to Turn a Handcrafted Process into an Assembly Line

Gamgee is part of Y Combinator's Summer 2026 batch. This $4 million seed round included, besides Founders Fund, Celine Halioua (founder and CEO of canine longevity company Loyal), Steve Eidelman (founder of Modern Animal), Arash Ferdowsi (co-founder of Dropbox), and Gokul Rajaram (creator of Google AdSense).

Founders Fund partner Amin Mirzadegan gave the reason for investment in the press release as the person, not the technology: Paul crossed several disciplines for a dog, taught himself entirely new fields, and kept pushing forward where most people would have stopped.

The company's goal is to industrialize the process that Conyngham manually navigated once: sequence the tumor and paired healthy tissue of each dog, find mutations unique to that cancer, identify tumor-specific neoantigens, design a personalized mRNA vaccine that teaches the immune system to target these points, and manage the entire chain from veterinary consultation, sequencing, design, production, treatment to follow-up.

Clinical studies are being conducted in Australia, with partners including UNSW, the University of Queensland, and the Garvan Institute of Medical Research. Enrollment is currently limited to eastern Australia; participating dogs receive the investigational vaccine for free, with eligibility determined by the study protocol and participating veterinary oncologists. The company stated it is in discussions with regulators, following the US Department of Agriculture (USDA) "patient-specific veterinary biologic products" pathway.

Regarding this funding round, Gamgee stated the money is to initiate a clinical trial to validate the personalized treatment plan developed for Rosie. Conyngham previously admitted on X that the company is recruiting veterinary oncologists and trial partners and seeking funding for a more rigorous study — this amounts to acknowledging that the evidence supporting its core claim is not yet in the form that regulators, veterinarians, or cautious pet owners would ultimately require.

Why Dogs?

Choosing dogs isn't just because Conyngham had one at home.

Comparative oncology is a field with decades of history. Spontaneous tumors in pet dogs share many biological, genetic, and histological features with human tumors. More importantly, they retain the naturally occurring complexity of drug resistance, metastasis, and tumor-host immune interactions, which are difficult to replicate in mouse models. The US National Cancer Institute has a dedicated Comparative Oncology Program, and the "Cancer Moonshot" initiative has also driven resources in this direction.

From an industry perspective, the canine track also attracts because of shorter regulatory pathways, lower costs, and faster trial cycles. There are already players: Torigen makes autologous tumor cell vaccines, ELIAS Animal Health works on autologous cancer vaccines combined with T-cell therapy, and Yale's EGFR/HER2 vaccine takes another more universal route, not requiring tumor samples. Gamgee's differentiation lies in "N-of-1" — a unique vaccine for each dog, not a universal target.

Conyngham has also set long-term goals for the company beyond pet healthcare: to make personalized mRNA vaccines deliverable by any veterinary oncologist and to establish N-of-1 medicine as a better treatment model across species, including humans.

For Cancer Vaccines, the Race Is About Speed

Looking at these two pieces of news together, they both eventually circle back to the same issue: time.

For Merck and Moderna, the positive Phase III results proved the feasibility of "making a separate drug for each patient." However, it took five years from finalizing the algorithm plan to the Phase III results and ten years from project initiation to today.

For Rosie, it took about two years from diagnosis to the first shot, with three months spent on the 100-page document for ethical approval, while the time she could wait was only months.

The core contradiction of personalized treatment has never been just "can it be designed," but rather whether the total time of the chain — design, approval, production, administration — can be compressed within the timeframe the patient (or sick dog) can afford. AI shortens the very first part of the chain — finding targets, designing sequences. The remaining parts have not yet been compressed to the same degree.

Conyngham's statement, "we couldn't make her next vaccine fast enough," refers precisely to this.

What Gamgee is essentially buying with $4 million is the ability to streamline this chain and obtain evidence acceptable to regulators and veterinarians. The success of this depends on the data from the Australian clinical study, not on how moving Rosie's story is.

Until then, the only responsible advice for someone whose dog has just been diagnosed with cancer is still: go to a qualified veterinary oncologist, not treat a viral case as a treatment plan.

Reference Links:

https://www.reuters.com/legal/litigation/merck-moderna-say-melanoma-skin-cancer-vaccine-meets-goals-large-trial-2026-08-19/

https://www.gamgee.io/story/

https://x.com/paul_conyngham/status/2090502003449590254

This article is from WeChat public account "Almost Human" (ID: almosthuman2014), author: Machine Heart Focused on AI

Preguntas relacionadas

QWhat was the main reason for Moderna's significant stock price surge mentioned in the article?

AModerna's stock price surged due to news of a successful cancer vaccine, which involves reading the genetic mutations in a patient's tumor and then creating a personalized mRNA vaccine for that patient.

QWho is Paul S. Conyngham and what did he do for his dog Rosie?

APaul S. Conyngham is an AI entrepreneur with no medical background who used AI tools like ChatGPT, Gemini, and Grok to design a personalized mRNA cancer vaccine for his dog Rosie, who had mast cell tumors.

QWhat is the primary goal of Conyngham's new company, Gamgee?

AThe primary goal of Gamgee is to industrialize the process Conyngham used for Rosie, creating a replicable pipeline to provide personalized mRNA cancer vaccines for more dogs with cancer.

QAccording to the article, what is 'comparative oncology' and why is studying canine cancer relevant?

AComparative oncology is a field that studies spontaneous tumors in pet dogs, which share many biological, genetic, and histological features with human tumors. Studying them is valuable because they retain the complexity of natural drug resistance, metastasis, and tumor-host immune interactions, which are hard to replicate in mouse models.

QWhat is identified as the core challenge for personalized cancer treatments like mRNA vaccines, both for humans and dogs?

AThe core challenge is the total time required for the entire pipeline—from design and regulatory approval to production and administration—to be compressed enough to fall within the timeframe the patient (or pet) can afford to wait.

Lecturas Relacionadas

Generating Profits for Seven Consecutive Quarters, Emerging Markets Carry Trade Outperforms Everything

For the seventh consecutive quarter, dollar-funded emerging market carry trades have delivered positive returns, marking the longest winning streak since 2008. According to Bloomberg's index, this strategy has gained approximately 22% since late 2024, outperforming U.S. Treasuries, emerging market sovereign, and corporate dollar debt. The core of the trade involves borrowing low-interest currencies like the U.S. dollar, euro, or yen to invest in high-yielding emerging market assets, such as Turkish lira bonds offering over 40% returns. Returns were amplified by favorable currency moves, with the dollar weakening against most emerging market currencies and other traditional funding currencies. For instance, the trade gained 48% on the Colombian peso in the past year. A key test came in August 2024 with a historic joint U.S.-Japan currency intervention, which caused only a modest 1% dip in the carry trade risk premium as investors shifted funding from the yen to the euro and Swiss franc. Looking ahead, the primary risk is the timing of Federal Reserve policy changes. While persistent inflation allows the Fed to hold rates, a rapid rise in long-term U.S. yields could threaten the trade. Another concern is crowding, as massive inflows increase vulnerability to a sudden reversal. High interest rates in regions like Latin America and Eastern Europe, supported by external factors like Middle East tensions and energy prices, continue to sustain the opportunity. Major investors remain engaged, favoring currencies like the Mexican peso, South African rand, and Turkish lira.

marsbitHace 13 min(s)

Generating Profits for Seven Consecutive Quarters, Emerging Markets Carry Trade Outperforms Everything

marsbitHace 13 min(s)

Tsinghua and Whiton Mentor-Disciple Team Cracks 40-Year-Old Mystery, Core Math All Written by GPT, Anyone Could Do It

Tsinghua and Wharton researchers have used GPT-5.6 Sol Pro to solve a 40-year-old open problem in optimization theory, proving a fundamental limit for gradient descent. They demonstrated that by adjusting only the step size sequence—without adding momentum or changing the algorithm's structure—the convergence rate of gradient descent cannot exceed Ω(T^{-1.9319}). This establishes a mathematical ceiling, showing that structural modifications are necessary to achieve the fastest possible convergence rates like O(1/T²). The core proof, involving a geometric construction based on "resisting oracles," was entirely generated through iterative interaction with the AI. The proof was then formally verified using the Lean 4 theorem prover, achieving zero "sorry" or "admit" statements, confirming its logical correctness without human intervention in the non-trivial mathematical steps. This result bridges the gap between the known O(T^{-1.2716}) rate achieved by the "silver stepsize" sequence and the newly proven impossibility bound. The work suggests a new paradigm where researchers can leverage general-purpose AI to explore and formally verify complex theoretical proofs.

marsbitHace 23 min(s)

Tsinghua and Whiton Mentor-Disciple Team Cracks 40-Year-Old Mystery, Core Math All Written by GPT, Anyone Could Do It

marsbitHace 23 min(s)

Anthropic Admits Fault, Evidence of Secretly Downgrading Claude's Intelligence

Anthropic publicly apologized after users discovered a hidden A/B test in Claude Code (versions 2.1.237+) that seemingly "dumbed down" the model. Developer argofowl found that selecting the "high" reasoning effort was being mapped internally to a value of "10," which previously corresponded to the "low" setting. While Anthropic engineers clarified this was only a change to the numerical mapping scale and assured it did not affect performance based on internal evaluations, the lack of communication about the test sparked widespread user backlash and self-tests on social media. Separately, significant complaints emerged about the flagship Opus 5 model, with users reporting it became "unstable," prone to lazy outputs, factual errors, and repetitive corrections. An Anthropic engineer acknowledged Opus 5's performance instability, calling its resolution a top priority. The incident highlights a growing industry-wide rift between improving benchmark scores and declining user-perceived quality and reliability. It underscores the lack of transparency in continuous model updates, where server-side changes, A/B tests, and configuration adjustments occur without clear user notification, eroding trust as AI models become critical infrastructure.

marsbitHace 23 min(s)

Anthropic Admits Fault, Evidence of Secretly Downgrading Claude's Intelligence

marsbitHace 23 min(s)

Unpacking the Truth Behind On-chain Assets: Leverage, Liquidity, and Risk

The article analyzes the concept of "real-world asset" (RWA) tokenization, arguing that while tokenizing assets on-chain is a useful step, it is far from transformative on its own. The author compares it to placing a barcode on a shipping container—it enables identification but does not build the necessary market infrastructure. The core argument is that true value emerges not from tokenization, but from integrating these tokens into DeFi systems where they can be valued, financed, hedged, traded, and liquidated under stress. Key challenges identified include: 1. **Multiple Time Clocks**: A fundamental tension exists between blockchain's 24/7 settlement and the slower, business-hour-dependent processes of traditional markets, custody, and redemption. This "duration mismatch" can create dangerous liquidity gaps during crises. 2. **Liquidity Misconceptions**: True liquidity is not measured by Total Value Locked (TVL) or trading pairs, but by the ability to exit a position within a required timeframe at an acceptable price. It requires analyzing multiple exit paths and stress-testing scenarios. 3. **Leverage and Risk**: Leverage unlocks economic utility (e.g., using tokenized assets as collateral) but also introduces fragility. Risk models must account for more than asset volatility, incorporating factors like legal enforceability, oracle freshness, and market structure. Paradoxically, a "safer" asset like tokenized Treasury bonds could require a higher collateral discount than ETH due to slower, less-proven liquidation mechanisms. 4. **A Risk Graph**: RWA risk should be modeled as a network of interconnected dependencies (e.g., issuers, custodians, oracles, stablecoin pools), not a single score. Failures can propagate through this graph, turning operational issues into systemic liquidity crises. The article states that tokenized government bonds are merely an entry point, while more complex frontiers like computing power and energy assets present greater challenges and opportunities. It also examines the interplay and risks between tokenized stocks and perpetual futures contracts. The conclusion is that the future lies not in "tokenizing everything," but in building robust market layers where tokenized rights become resilient financial primitives within a programmable capital system. The token is just the barcode; the market is the machine.

marsbitHace 38 min(s)

Unpacking the Truth Behind On-chain Assets: Leverage, Liquidity, and Risk

marsbitHace 38 min(s)

The End of Mathematics: 40 Top Mathematicians Gather at Secret OpenAI Meeting

In August 2026, OpenAI hosted a closed-door summit with approximately 40 leading mathematicians, including recent Fields Medalist Jacob Tsimerman and OpenAI researcher Sébastien Bubeck. The meeting, spurred by a series of recent AI breakthroughs in mathematics, grappled with the potential existential threat AI poses to the field. The backdrop includes several high-profile AI achievements: OpenAI models disproving long-standing conjectures like the unit distance problem, generating 10 new mathematical discoveries, and Anthropic's Claude aiding in constructing complex multidimensional objects. These results often bypass traditional academic pipelines, appearing directly on social media. The mathematical community is divided. Over 3000 researchers signed the "Leiden Statement," advocating for responsible AI use and verification. Others resist AI entirely to preserve human-centric mathematics. A key concern is AI's current inability to *explain* proofs, particularly the difficult steps, which is central to mathematical understanding. At the summit, Bubeck outlined four potential futures: mathematics becoming like collaborative software engineering, a compute-driven field like physics, a curatorial exercise where humans interpret AI output, or a mass transition of mathematicians into AI safety. While emphasizing that "mathematics only makes sense when mathematicians learn from it," no consensus was reached. The event highlights a profound moment of reflection. As AI demonstrates increasing competence in solving complex problems, mathematicians are forced to question their future role and the very meaning of their discipline.

marsbitHace 43 min(s)

The End of Mathematics: 40 Top Mathematicians Gather at Secret OpenAI Meeting

marsbitHace 43 min(s)

Trading

Spot